Search Results

Association between smoking cessation and risk for type 2 diabetes, stratified by post-cessation weight change: A systematic review and meta-analysis

• Authors : Yu, Yifan; Yu, Yifan; Li, Yan

Subjects: Tobacco cessation; Smoking-related diabetes; Post-cessation weight change

Record details

Identification of novel type 1 and type 2 diabetes genes by co-localization of human islet eQTL and GWAS variants with colocRedRibbon.

• Authors : Piron, Anthony; Szymczak, Florian; Folon, Lise

Subjects: Sciences bio-médicales et agricoles; GWAS; co-localization

• Source: Cell Genomics

Record details

Protocol for a 1-year randomised, controlled, parallel group, open-label trial on the effects and feasibility of time-restricted eating in individuals with type 2 diabetes - The REStricted Eating Time in the treatment of type 2 diabetes (RESET2) trial

• Authors : Termannsen, Anne-Ditte; Varming, Annemarie; Bjerre, Natasja

Subjects: diabetes mellitus type 2; diet; fasting

• Source: Termannsen , A-D , Varming , A , Bjerre , N , Wodschow , H Z , Hansen , G S , Jensen , N J , Persson , F , Bagger , J I , Panda , S , Finlayson , G , Ewers , B , Hansen , D L , Nørgaard , K , Rungby

Record details

Canagliflozin reduces oral loop diuretic intensification in patients with type 2 diabetes:A participant-level pooled analysis of the CANVAS and CREDENCE trials

• Authors : Chatur, Safia; Vaduganathan, Muthiah; Fletcher, Robert A.

Subjects: Chronic kidney disease; Heart failure; Loop diuretic

• Source: Chatur, S, Vaduganathan, M, Fletcher, R A, Perkovic, V, Heerspink, H, Arnott, C, Pollock, C, Mahaffey, K W, Neal, B, Jardine, M, Solomon, S D & Neuen, B L 2025, 'Canagliflozin reduces oral loop

Record details

Downsizing chronic disease management programs for type 2 diabetes patients during the COVID-19 pandemic:changes in healthcare utilization patterns

• Authors : Rijpkema, Corinne; Ramerman, Lotte; Peters, Lilian

Subjects: COVID-19; diabetes mellitus type 2; electronic health records

• Source: Rijpkema, C, Ramerman, L, Peters, L, Muris, J, Olde Hartman, T, Homburg, M, Bos, I & Verheij, R 2025, 'Downsizing chronic disease management programs for type

Record details

Uncovering actionable cardiovascular risk subgroups in type 2 Diabetes:A latent class analysis

• Authors : Geurten, Rose J.; Hameleers, Niels; Struijs, Jeroen N.

Subjects: Cardiovascular disease; Latent Class Analysis; Population Health Management

• Source: Geurten, R J, Hameleers, N, Struijs, J N, Bilo, H JG, Ruwaard, D & Elissen, A MJ 2025, 'Uncovering actionable cardiovascular risk subgroups in type

Record details

Effects of dapagliflozin on sodium excretion, blood pressure and volume status in patients with type 2 diabetes and/or chronic kidney disease:The DAPASALT trial

• Authors : Beernink, Jelle; Jongs, Niels; Mosterd, Charlotte M.

Subjects: clinical trial; dapagliflozin; drug mechanism

• Source: Beernink, J, Jongs, N, Mosterd, C M, Scholtes, R A, Caldwell-McGee, A, Casillas, D, Driscoll, L, Greasley, P J, Karlsson, C, Hammarstedt, A, Sridhar, V S, Muskiet, M H A, Laverman, G D, Cherney, D Z

Record details

The burden of depression among patients with type 2 diabetes:An umbrella review of systematic reviews

• Authors : Wulandari, Nora; Lamuri, Aly; van Hasselt, Fenneke

Subjects: Depression; Meta-analyses; Prevalence

• Source: Wulandari, N, Lamuri, A, van Hasselt, F, Feenstra, T & Taxis, K 2025, 'The burden of depression among patients with type 2 diabetes : An

Record details

Effect of spironolactone wash-out on albuminuria after long-term treatment in individuals with type 2 diabetes and high risk of kidney disease—An observational follow-up of the PRIORITY study

• Authors : Wasehuus, Victor; Rotbain Curovic, Viktor; Tofte, Nete

Subjects: chronic kidney disease; diabetes complications; drug mechanism

• Source: the PRIORITY Study group, Wasehuus, V, Rotbain Curovic, V, Tofte, N, Lindhardt, M, Currie, G, Delles, C, Frimodt-Møller, M, Mischak, H, von der Leyen, H, Hansen, T W, Kümler, T, Persson, F &

Record details

Mechanistic evaluation of ertugliflozin in patients with type 2 diabetes and heart failure

• Authors : Lytvyn, Yuliya; Scholtes, Rosalie A.; Boorsma, Eva M.

Subjects: ertugliflozin; heart failure; SGLT2 inhibition

• Source: Lytvyn, Y, Scholtes, R A, Boorsma, E M, Sridhar, V S, Kugathasan, L, Liu, H, Lovblom, L E, Handoko, L, Mosterd, C M, Floras, J S, Burns, K, Osuntokun, T, Voors, A, van Raalte, D H, Heerspink, H J L &

Record details